BACKGROUND: Hyperkalemia is observed in chronic kidney disease patients and may be a risk factor for life-threatening arrhythmias and death. Race/ethnicity may be important modifiers of the potassium-mortality relationship in maintenance hemodialysis (MHD) patients given that potassium intake and excretion vary among minorities. METHODS: We examined racial/ethnic differences in baseline serum potassium levels and all-cause and cardiovascular mortality using Cox proportional hazard models and restricted cubic splines in a cohort of 102,241 incident MHD patients. Serum potassium was categorized into 6 groups: ≤3.6, >3.6 to ≤4.0, >4.0 to ≤4.5 (reference), >4.5 to ≤5.0, >5.0 to ≤5.5, and >5.5 mEq/L. Models were adjusted for case-mix and malnutrition-inflammation cachexia syndrome (MICS) covariates. RESULTS: The cohort was composed of 50% whites, 34% African-Americans, and 16% Hispanics. Hispanics tended to have the highest baseline serum potassium levels (mean ± SD: 4.58 ± 0.55 mEq/L). Patients in our cohort were followed for a median of 1.3 years (interquartile range 0.6-2.5). In our cohort, associations between higher potassium (>5.5 mEq/L) and higher mortality risk were observed in African-American and whites, but not Hispanic patients in models adjusted for case-mix and MICS covariates. While in Hispanics only, lower serum potassium (<3.6 mEq/L) levels were associated with higher mortality risk. Similar trends were observed for cardiovascular mortality. CONCLUSIONS: Higher potassium levels were associated with higher mortality risk in white and African-American MHD patients, whereas lower potassium levels were associated with higher death risk in Hispanics. Further studies are needed to determine the underlying mechanisms for the differential association between potassium and mortality across race/ethnicity.
BACKGROUND:Hyperkalemia is observed in chronic kidney diseasepatients and may be a risk factor for life-threatening arrhythmias and death. Race/ethnicity may be important modifiers of the potassium-mortality relationship in maintenance hemodialysis (MHD) patients given that potassium intake and excretion vary among minorities. METHODS: We examined racial/ethnic differences in baseline serum potassium levels and all-cause and cardiovascular mortality using Cox proportional hazard models and restricted cubic splines in a cohort of 102,241 incident MHD patients. Serum potassium was categorized into 6 groups: ≤3.6, >3.6 to ≤4.0, >4.0 to ≤4.5 (reference), >4.5 to ≤5.0, >5.0 to ≤5.5, and >5.5 mEq/L. Models were adjusted for case-mix and malnutrition-inflammation cachexia syndrome (MICS) covariates. RESULTS: The cohort was composed of 50% whites, 34% African-Americans, and 16% Hispanics. Hispanics tended to have the highest baseline serum potassium levels (mean ± SD: 4.58 ± 0.55 mEq/L). Patients in our cohort were followed for a median of 1.3 years (interquartile range 0.6-2.5). In our cohort, associations between higher potassium (>5.5 mEq/L) and higher mortality risk were observed in African-American and whites, but not Hispanic patients in models adjusted for case-mix and MICS covariates. While in Hispanics only, lower serum potassium (<3.6 mEq/L) levels were associated with higher mortality risk. Similar trends were observed for cardiovascular mortality. CONCLUSIONS: Higher potassium levels were associated with higher mortality risk in white and African-American MHD patients, whereas lower potassium levels were associated with higher death risk in Hispanics. Further studies are needed to determine the underlying mechanisms for the differential association between potassium and mortality across race/ethnicity.
Authors: Patrick H Pun; Ruediger W Lehrich; Emily F Honeycutt; Charles A Herzog; John P Middleton Journal: Kidney Int Date: 2010-09-01 Impact factor: 10.612
Authors: Kei Hang K Chan; Sara A Chacko; Yiqing Song; Michele Cho; Charles B Eaton; Wen-Chih H Wu; Simin Liu Journal: J Nutr Date: 2015-01-07 Impact factor: 4.798
Authors: Larisa H Cavallari; Lucy A Fashingbauer; Amber L Beitelshees; Vicki L Groo; Mary R Southworth; Marlos A G Viana; Randall E Williams; Stephanie H Dunlap Journal: Pharmacotherapy Date: 2004-06 Impact factor: 4.705
Authors: Martha L Daviglus; Gregory A Talavera; M Larissa Avilés-Santa; Matthew Allison; Jianwen Cai; Michael H Criqui; Marc Gellman; Aida L Giachello; Natalia Gouskova; Robert C Kaplan; Lisa LaVange; Frank Penedo; Krista Perreira; Amber Pirzada; Neil Schneiderman; Sylvia Wassertheil-Smoller; Paul D Sorlie; Jeremiah Stamler Journal: JAMA Date: 2012-11-07 Impact factor: 56.272
Authors: Amelie Bernier-Jean; Germaine Wong; Valeria Saglimbene; Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Vanessa Garcia-Larsen; David W Johnson; Marcello Tonelli; Jörgen Hegbrant; Jonathan C Craig; Armando Teixeira-Pinto; Giovanni F M Strippoli Journal: Clin J Am Soc Nephrol Date: 2021-12-01 Impact factor: 8.237
Authors: Danai Bem; Daniel Sugrue; Ben Wilding; Ina Zile; Karin Butler; David Booth; Eskinder Tafesse; Phil McEwan Journal: Ren Fail Date: 2021-12 Impact factor: 2.606
Authors: Abiy Agiro; Ian Duling; James Eudicone; Jill Davis; Yasmin G Brahmbhatt; Kerry Cooper Journal: Hemodial Int Date: 2022-01-17 Impact factor: 1.543